Dacogen

Anemia, Refractory Anemia, Anemia + 6 more
Treatment
20 Active Studies for Dacogen

What is Dacogen

DecitabineThe Generic name of this drug
Treatment SummaryMyelodysplastic syndromes (MDS) are a group of blood disorders caused by abnormal cells in the bone marrow. MDS can lead to a decrease in white and red blood cells, as well as platelets. In some cases, MDS can develop into acute myeloid leukemia, which is very serious. Decitabine is a medication approved by the FDA in 2006 to treat MDS. It works by preventing DNA methyltransferase from working, leading to a decrease in the number of abnormal cells. Decitabine is usually given intravenously, but it can also be taken orally in combination with
Dacogenis the brand name
Dacogen Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Dacogen
Decitabine
1996
36

Effectiveness

How Dacogen Affects PatientsDecitabine is a drug that changes how certain genes work in the body. Taking decitabine can result in a decrease in white blood cells and platelets, and can be harmful to a fetus if taken by a pregnant woman. It is important for those taking decitabine to practice effective contraception and avoid pregnancy.
How Dacogen works in the bodyDecitabine is used to treat myelodysplastic syndromes, a type of cancer that affects the white blood cells. Decitabine works by stopping the action of enzymes that add a chemical tag to certain genes, called DNA methylation. This causes the cancer cells to stop growing and die. It also causes genes that suppress tumors to become active, working to stop the cancer from spreading. Decitabine may also change how genes are expressed, alter histone modifications, and activate pathways involved in DNA damage response. The overall effect is to slow or stop cancer cell growth.

When to interrupt dosage

The measure of Dacogen depends upon the diagnosed state, such as Chronic Myelomonocytic Leukemia, Anemia and Refractory anemias. The amount likewise fluctuates, in line with the delivery mode (e.g. Intravenous or Injection, powder, for solution) delineated in the table beneath.
Condition
Dosage
Administration
Myelodysplastic Syndrome
, 5.0 mg/mL, 50.0 mg, 35.0 mg
, Injection, powder, lyophilized, for solution, Intravenous, Injection, powder, lyophilized, for solution - Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Injection, Injection - Intravenous, Powder - Intravenous, Powder, Tablet, film coated, Oral, Tablet, film coated - Oral, Tablet, Tablet - Oral
IPSS High Risk
, 5.0 mg/mL, 50.0 mg, 35.0 mg
, Injection, powder, lyophilized, for solution, Intravenous, Injection, powder, lyophilized, for solution - Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Injection, Injection - Intravenous, Powder - Intravenous, Powder, Tablet, film coated, Oral, Tablet, film coated - Oral, Tablet, Tablet - Oral
Chronic Myelomonocytic Leukemia
, 5.0 mg/mL, 50.0 mg, 35.0 mg
, Injection, powder, lyophilized, for solution, Intravenous, Injection, powder, lyophilized, for solution - Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Injection, Injection - Intravenous, Powder - Intravenous, Powder, Tablet, film coated, Oral, Tablet, film coated - Oral, Tablet, Tablet - Oral
IPSS Risk Category Intermediate-1
, 5.0 mg/mL, 50.0 mg, 35.0 mg
, Injection, powder, lyophilized, for solution, Intravenous, Injection, powder, lyophilized, for solution - Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Injection, Injection - Intravenous, Powder - Intravenous, Powder, Tablet, film coated, Oral, Tablet, film coated - Oral, Tablet, Tablet - Oral
Anemia
, 5.0 mg/mL, 50.0 mg, 35.0 mg
, Injection, powder, lyophilized, for solution, Intravenous, Injection, powder, lyophilized, for solution - Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Injection, Injection - Intravenous, Powder - Intravenous, Powder, Tablet, film coated, Oral, Tablet, film coated - Oral, Tablet, Tablet - Oral
Anemia
, 5.0 mg/mL, 50.0 mg, 35.0 mg
, Injection, powder, lyophilized, for solution, Intravenous, Injection, powder, lyophilized, for solution - Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Injection, Injection - Intravenous, Powder - Intravenous, Powder, Tablet, film coated, Oral, Tablet, film coated - Oral, Tablet, Tablet - Oral
Refractory Anemia
, 5.0 mg/mL, 50.0 mg, 35.0 mg
, Injection, powder, lyophilized, for solution, Intravenous, Injection, powder, lyophilized, for solution - Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Injection, Injection - Intravenous, Powder - Intravenous, Powder, Tablet, film coated, Oral, Tablet, film coated - Oral, Tablet, Tablet - Oral
Anemia
, 5.0 mg/mL, 50.0 mg, 35.0 mg
, Injection, powder, lyophilized, for solution, Intravenous, Injection, powder, lyophilized, for solution - Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Injection, Injection - Intravenous, Powder - Intravenous, Powder, Tablet, film coated, Oral, Tablet, film coated - Oral, Tablet, Tablet - Oral
IPSS Risk Category Intermediate-2
, 5.0 mg/mL, 50.0 mg, 35.0 mg
, Injection, powder, lyophilized, for solution, Intravenous, Injection, powder, lyophilized, for solution - Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Injection, Injection - Intravenous, Powder - Intravenous, Powder, Tablet, film coated, Oral, Tablet, film coated - Oral, Tablet, Tablet - Oral

Warnings

There are 20 known major drug interactions with Dacogen.
Common Dacogen Drug Interactions
Drug Name
Risk Level
Description
2-Methoxyethanol
Major
The risk or severity of adverse effects can be increased when Decitabine is combined with 2-Methoxyethanol.
9-(N-methyl-L-isoleucine)-cyclosporin A
Major
The risk or severity of adverse effects can be increased when Decitabine is combined with 9-(N-methyl-L-isoleucine)-cyclosporin A.
Abatacept
Major
The risk or severity of adverse effects can be increased when Decitabine is combined with Abatacept.
Abetimus
Major
The risk or severity of adverse effects can be increased when Decitabine is combined with Abetimus.
Acteoside
Major
The risk or severity of adverse effects can be increased when Decitabine is combined with Acteoside.
Dacogen Toxicity & Overdose RiskDecitabine has been found to have mutagenic and damaging effects in certain tests on animals, including decreased weight and fertility in mice exposed to it in utero, and decreased sperm count and fertility in adult male mice treated with a high dose. An overdose of decitabine can cause decreased production of white and red blood cells and platelets, as well as other severe side effects. There is no antidote for decitabine overdose, so patients should be provided with supportive care.

Dacogen Novel Uses: Which Conditions Have a Clinical Trial Featuring Dacogen?

183 active research projects are currently underway to assess the potential of Dacogen to mitigate Anemia, Refractory Anemia and Myelodysplastic Syndrome.
Condition
Clinical Trials
Trial Phases
Myelodysplastic Syndrome
115 Actively Recruiting
Phase 2, Phase 1, Phase 3, Not Applicable, Early Phase 1
Anemia
1 Actively Recruiting
Phase 2
Anemia
0 Actively Recruiting
IPSS Risk Category Intermediate-1
0 Actively Recruiting
IPSS Risk Category Intermediate-2
0 Actively Recruiting
Refractory Anemia
5 Actively Recruiting
Phase 2, Phase 1
Chronic Myelomonocytic Leukemia
49 Actively Recruiting
Phase 1, Phase 2, Phase 3
Anemia
0 Actively Recruiting
IPSS High Risk
0 Actively Recruiting

Dacogen Reviews: What are patients saying about Dacogen?

5Patient Review
12/15/2011
Dacogen for Bone Marrow Disorders Occurring Before Leukemia
I've been on Dacogen for three months now, and it's going well. I have to get IV treatments every five days, followed by three weeks off. It's lowered my white blood cell count, so I've needed a few transfusions of red blood cells. But things are looking up – my hemoglobin is rising without any assistance, and I'm feeling stronger every day.
5Patient Review
4/25/2009
Dacogen for Bone Marrow Disorders Occurring Before Leukemia
4.7Patient Review
7/24/2011
Dacogen for Bone Marrow Disorders Occurring Before Leukemia
Dacogen has been working well for me over the past year and a half. My blood counts are finally in the safer range, but I have developed slightly increased levels of sugar in my blood, so I may need to start medication for diabetes.
3.7Patient Review
10/1/2011
Dacogen for Bone Marrow Disorders Occurring Before Leukemia
I've been on this medication since my diagnosis of myleodysplasia 23 months ago. My blood counts are now completely normal, but my white blood cells fluctuate a bit below normal.
3.3Patient Review
10/10/2009
Dacogen for Bone Marrow Disorders Occurring Before Leukemia
I've been on this treatment for a year now, and it seems to be working. I haven't needed blood transfusions, so that's good. Thank you, Jesus.
2Patient Review
7/7/2014
Dacogen for Bone Marrow Disorders Occurring Before Leukemia
My mother has leukemia and is currently taking Dacogne.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about dacogen

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is Dacogen chemo?

"Dacogen, in the form of decitabine, is an antineoplastic medication used to treat myelodysplastic syndromes, which are certain types of blood or bone marrow cancer. Generic forms of Dacogen are available."

Answered by AI

How is Dacogen administered?

"DACOGEN should be given at a dose of 15 mg/m2 over the course of 3 hours by continuous intravenous infusion. This should be repeated every 8 hours for 3 days. After this, cycles should be repeated every 6 weeks, but only if the patient has regained enough blood cells and platelets (ANC at least 1,000/µL and platelets at least 50,000/µL). A minimum of 4 cycles is recommended."

Answered by AI

What type of drug is Dacogen?

"The medicine Dacogen is used to treat symptoms of blood or bone marrow cancer, specifically myelodysplastic syndromes. It can be used on its own or with other medications, and belongs to a class of drugs known as antineoplastics and DNA methylation inhibitors."

Answered by AI

What is Dacogen drug used for?

"This medication is used to treat myelodysplastic syndromes (MDS), a group of disorders in which the bone marrow does not produce enough healthy blood cells. People with MDS may have problems such as infections, anemia, and easy bleeding/bruising."

Answered by AI

Clinical Trials for Dacogen

Have you considered Dacogen clinical trials? We made a collection of clinical trials featuring Dacogen, we think they might fit your search criteria.
Have you considered Dacogen clinical trials? We made a collection of clinical trials featuring Dacogen, we think they might fit your search criteria.
Have you considered Dacogen clinical trials? We made a collection of clinical trials featuring Dacogen, we think they might fit your search criteria.